FMR LLC lessened its stake in PepGen Inc. (NASDAQ:PEPG - Free Report) by 84.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 61,607 shares of the company's stock after selling 327,160 shares during the quarter. FMR LLC owned 0.19% of PepGen worth $527,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors have also recently modified their holdings of the stock. Point72 DIFC Ltd bought a new position in PepGen in the 2nd quarter valued at approximately $42,000. American Century Companies Inc. lifted its holdings in shares of PepGen by 19.9% during the second quarter. American Century Companies Inc. now owns 20,028 shares of the company's stock valued at $320,000 after purchasing an additional 3,326 shares in the last quarter. Rhumbline Advisers boosted its position in shares of PepGen by 36.1% during the second quarter. Rhumbline Advisers now owns 18,853 shares of the company's stock valued at $301,000 after buying an additional 5,002 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new stake in PepGen in the 3rd quarter worth about $95,000. Finally, Renaissance Technologies LLC purchased a new position in PepGen in the 2nd quarter worth about $192,000. Hedge funds and other institutional investors own 58.01% of the company's stock.
PepGen Price Performance
Shares of NASDAQ:PEPG traded up $0.03 during trading on Thursday, hitting $4.09. The company's stock had a trading volume of 59,624 shares, compared to its average volume of 131,880. The firm has a market cap of $133.32 million, a price-to-earnings ratio of -1.37 and a beta of 1.56. The company has a 50-day moving average of $6.06 and a 200-day moving average of $10.42. PepGen Inc. has a 12 month low of $2.90 and a 12 month high of $19.30.
Analysts Set New Price Targets
PEPG has been the topic of a number of recent analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $26.00 price target on shares of PepGen in a report on Friday, November 8th. Bank of America downgraded shares of PepGen from a "neutral" rating to an "underperform" rating and set a $3.00 target price for the company. in a research report on Monday. Finally, Wedbush lowered their price target on PepGen from $19.00 to $12.00 and set an "outperform" rating on the stock in a report on Friday, November 8th.
Check Out Our Latest Stock Report on PEPG
PepGen Profile
(
Free Report)
PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.
Read More
Before you consider PepGen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PepGen wasn't on the list.
While PepGen currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
